Clinical trials: Cocaine Dependence
Cocaine Addiction, Cocaine Dependence
Vigabatrin for the Treatment of Cocaine Dependency
The objective of this 26-28 week study is to demonstrate that the rate of cocaine dependent subjects treated with CPP-109 vigabatrin in addition to counseling, who completely stop use of cocaine in the last 2 weeks of the study's…
- Trial name
- NCT01281202
- Testing
- Vigabatrin
- Where
- 13 sites in United States
- Volunteers
- 207 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Substance Use Disorders, Opioid Use Disorder
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
The overarching goal of this study phase, Phase II component is to implement Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders (EDITOR) device in substance use disorder (SUD)…
- Conditions
- Substance Use Disorders, Opioid Use Disorder, Alcohol Use Disorder, Cocaine Use Disorder
- Trial name
- EDITOR (NCT06434818)
- Testing
- EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance), CBOT with olfactory stimulants & OFC tasks
- Where
- 3 sites in United States
- Volunteers
- 300 people
- Sponsor
- Evon Medics LLC
Cocaine Use Disorder, Cocaine Dependence
TDCS for Cocaine Addiction Craving
Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation in which low level electrical currents are applied to the scalp in order to alter brain function.
- Trial name
- NCT03833583
- Testing
- Soterix Medical mini-CT tDCS stimulator
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Soterix Medical
Cocaine Use Disorder, Cocaine Dependence
TDCS to Reduce Craving in Cocaine Addiction- Phase 2 Study
Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation in which low level electrical currents are applied to the scalp in order to alter brain function.
- Trial name
- NCT04994821
- Testing
- transcranial direct current stimulator (tDCS), Cognitive Reappraisal
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Soterix Medical
Cocaine Abuse
ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine
The purpose of this study is to assess the safety and tolerability of ALKS33-BUP when administered to opioid-experienced cocaine abusers.
- Trial name
- NCT01366001
- Testing
- ALKS 33-BUP, ALKS 33
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Alkermes, Inc.
Opioid Dependence, Opioid Related Disorders
A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse
This is a randomized, 4-sequence, 2-period, double-blind, placebo controlled study in male and female subjects with an American Psychiatric Association Diagnostic and Statistical Manual DSM-IV-TR diagnosis of cocaine abuse.
- Conditions
- Opioid Dependence, Opioid Related Disorders, Cocaine Dependence
- Trial name
- RBP-8000 (NCT01846481)
- Testing
- RBP-8000 100 mg, Cocaine, RBP-8000 200 mg
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Indivior Inc.
Cocaine Dependence, Cocaine Addiction
A Placebo-Controlled Study of a Combination of Metyrapone and Oxazepam in Cocaine Addiction
Subjects will be randomly assigned to receive either one of the two potential dose combinations of the study medications or placebo over 6 weeks.
- Trial name
- NCT00567814
- Testing
- Metyrapone, Oxazepam
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Embera NeuroTherapeutics, Inc.
Cocaine Addiction
Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects
The primary objective of this study is to assess the efficacy and safety of TV-1380 [Recombinant human serum albumin (HSA) mutated butyrylcholinesterase (AlbuBChE)] in facilitating abstinence in cocaine-dependent subjects.
- Trial name
- NCT01887366
- Testing
- TV-1380 150 mg, TV-1380 300 mg
- Where
- 19 sites in United States, Spain
- Volunteers
- 208 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Cocaine Dependence
Vigabatrin for Treatment of Cocaine Dependence
The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be cocaine-free in the last 2 weeks of treatment.
- Trial name
- NCT00611130
- Testing
- vigabatrin
- Where
- 11 sites in United States
- Volunteers
- 186 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Cocaine Dependence
Study of Safety and Potential Efficacy of SYN117 in Cocaine Dependent Volunteers
This study will assess the potential interaction and subjective effects between intravenous cocaine and SYN117 in non-treatment seeking cocaine dependant subjects
- Trial name
- NCT00656357
- Testing
- SYN117 80 mg, SYN117 160 mg, Cocaine 10mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Biotie Therapies Inc.
Cocaine Dependency
A Safety, Tolerability and Pharmacokinetic Study of CPP-115
Primary Objective: To evaluate the safety and tolerability of ascending single oral doses of CPP-115 Secondary Objective: To determine the pharmacokinetic profiles of CPP-115 following administration of a ascending single oral…
- Trial name
- NCT01493596
- Testing
- CPP-115
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Stimulant Use Disorder
Smartphone Services for Stimulant Use Disorder
This study is testing two approaches to treating Stimulant Use Disorder, or problems with cocaine, crack, methamphetamine, etc. Stimulant Use Disorder is a national epidemic in the U.S.
- Trial name
- NCT07092059
- Testing
- Smartphone digital therapeutic system
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- DynamiCare Health
Cocaine-related Disorder
Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)
This study assessed whether AFQ056 had a beneficial effect by reducing cocaine use in Cocaine Use Disorder (CUD) patients as assessed by Timeline Follow-Back cocaine self-report.
- Trial name
- NCT03242928
- Testing
- AFQ056
- Where
- 8 sites in Argentina, Spain and 1 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Addiction, Opioid Dependence
Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction
The purpose of this study is determine the safety, efficacy and tolerability of a novel drug APH-1501 as a pharmacotherapy for Opioid Dependence. The investigators will evaluate the safety of escalating doses APH-1501.
- Conditions
- Addiction, Opioid Dependence, Opioid Withdrawal
- Trial name
- NCT03813095
- Testing
- APH-1501
- Volunteers
- 32 people
- Sponsor
- Aphios